SGLT2 inhibitors are known to have cardioprotective effects in patients with diabetes, which can be attributed to their hemodynamic effects, improvements in vascular function, and positive effects on cardiac remodeling [44, 45]. This evidence concerns the gene SLC5A2 and diabetes mellitus.